Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00326885 · ClinicalTrials.gov registry record · Phase 2
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
A Phase 2 study of Malignant Ascites, sponsored by Neovii Biotech.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 18
- Study locations
NCT00326885: Completed Phase 2 study of Malignant Ascites, sponsored by Neovii Biotech.
NCT00326885 is a Phase 2 study of Malignant Ascites that has completed, run by Neovii Biotech. The registered enrollment target is 32 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower). The trial reports 18 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00326885, a Phase 2 study of Malignant Ascites, has completed, sponsored by Neovii Biotech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 18
- Study locations
Study Summary
The purpose of this study is to determine whether the investigational drug catumaxomab is a safe and effective treatment for recurrent symptomatic malignant ascites.
Primary Outcome
The parameter to be estimated is the proportion of patients who achieve at least a 4-fold increase in their puncture/paracentesis-free interval. The pretreatment interval is defined as the length of time between the patient's most recent paracentesis (baseline) and the subsequent paracentesis necessitated by her increasing ascites-related symptoms. The post-treatment interval is defined as the time between the last dose of catumaxomab plus 1 day to the time of recurrence of ascites requiring the
Conditions Studied
Interventions
- DRUG catumaxomab
Study Locations (18)
California
- University of San Diego - La Jolla
- Stanford University Hospital and Clinics - Stanford
Florida
- University of Miami - Miami
- Florida Hospital Cancer Center - Orlando
Massachusetts
- Dana Farber Cancer Institute - Boston
- Massachusetts General Hospital - Boston
Arizona
- University of Arizona Cancer Center - Tucson
Indiana
- Northern Indiana Cancer Research Consortium - South Bend
Kentucky
- University of Louisville Cancer Center - Louisville
Maryland
- Johns Hopkins Medical Institute - Baltimore
Michigan
- Wayne State University - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2006-06 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
What the finished NCT00326885 record still lists
NCT00326885 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Malignant Ascites appearing as the primary indexed condition, and to 1 intervention - of which catumaxomab is the first listed.
NCT00326885 lists 18 locations in 15 states (California, Florida, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT00326885 about?
NCT00326885 is a clinical study titled "Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites". The purpose of this study is to determine whether the investigational drug catumaxomab is a safe and effective treatment for recurrent symptomatic malignant ascites.
What is the current status of trial NCT00326885?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2006-06. Estimated completion is 2010-08.
What conditions does trial NCT00326885 study?
This clinical trial studies the following conditions: Malignant Ascites.
What interventions are being tested in trial NCT00326885?
The interventions under investigation include: catumaxomab (DRUG).
Who is sponsoring clinical trial NCT00326885?
This trial is sponsored by Neovii Biotech, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00326885 being conducted?
This trial has 18 study locations across Arizona, California, Florida, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Ascites
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00326885's enrollment target sits among peer trials
32 1563rd of 2000 higher than 423 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia